BioCentury
ARTICLE | Clinical News

TiGenix speeds Cx601 timeline

March 7, 2017 11:22 PM UTC

TiGenix N.V. (Euronext:TIG; NASDAQ:TIG) said FDA agreed to a shortened Phase III trial design that would allow the company to submit a BLA for Cx601 one year earlier than originally planned. The study is evaluating the regenerative candidate to treat perianal fistulas in patients with Crohn's disease.

On Tuesday, TiGenix gained €0.03 to €0.75 in Brussels and $0.66 to $15.60 on NASDAQ...

BCIQ Company Profiles

TiGenix N.V.